Overview of MARIPOSA Study

Opinion
Video

Panelists discuss insights from the MARIPOSA study on first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), highlighting the efficacy of amivantamab-lazertinib over osimertinib, the importance of managing adverse events, adherence to National Comprehensive Cancer Network guidelines, and the need for patient engagement in treatment discussions to address unmet needs.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content
Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

ONCOLOGY Staff
December 28th 2024
Article

Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.